Community Oncology Alliance

 

Community Oncology Alliance
E

Biosimilars: What Patients Need to Know

By Community Oncology Alliance FEATURING E. Randolph Broun, Rachel Saks
By Community Oncology Alliance FEATURING E. Randolph Broun, Rachel Saks
0 views
November 4, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
2022 Community Oncology Advocacy Summit
27:01
Community Oncology Alliance

How To Engage Patients & Physicians as Advocates

Feat. C. Klock, L. Poiry
27:47
Community Oncology Alliance

Making It Local: How States Are Reforming Cancer Policy

Feat. N. Ferreyros, J. Lee
39:25
Community Oncology Alliance

Federal Cancer Care Policy: Updates From Capitol Hill

Feat. M. Atkins, T. Okon, H. Vyas
39:48
Community Oncology Alliance

Biosimilars: What Patients Need to Know

Feat. E. Randolph Broun, R. Saks
30:10
Community Oncology Alliance

Understanding the Impact of Disparities & Social Determinants of…

Feat. M. Kruczynski, A. Rahman, S. Sabo-Wagner
29:57
Community Oncology Alliance

How Do We Define Quality Cancer Care?

Feat. B. Gamble